IN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial

IN8BIO Inc. has announced new clinical data from its investigator-sponsored Phase 1 trial of INB-200 and Company-sponsored Phase 2 trial of INB-400 for the treatment of newly diagnosed glioblastoma. The results were presented in poster and oral sessions at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting on November 21 and 22, 2025. Across both trials, 17 patients were treated with the Company’s DeltEx DRI gamma-delta T cells, with 14 patients receiving repeated doses. These patients achieved a median progression-free survival of 13.0 months, compared to 6.6 months for 10 patients who received only the standard-of-care Stupp protocol. Median overall survival for patients treated with repeated DeltEx DRI doses has not yet been reached and was reported at 16.4+ months as of October 31, 2025, while the standard-of-care group had a median overall survival of 11.0 months. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-292057), on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here